Basilea Pharmaceutica AG represents values of innovation, collaboration, and patient-centric approach. As a leading biopharmaceutical company, Basilea focuses on discovering, developing, and marketing novel medications to address critical medical needs. With a commitment to scientific excellence, the company strives to improve patient outcomes and quality of life through its research and development efforts. Basilea embraces a corporate philosophy that emphasizes integrity, transparency, and ethical conduct in all aspects of its operations. By consistently delivering breakthrough therapies, Basilea Pharmaceutica AG aims to make a meaningful impact on global healthcare.

Basilea Pharmaceutica AG is primarily present in several key countries and regions. The company is based in Switzerland and has a significant presence in Europe, including Germany, France, the United Kingdom, and Italy. It also operates in the United States, where it has a commercial presence and collaborates with local partners. Basilea Pharmaceutica AG strives to expand its global reach, with a focus on markets in Asia, particularly China and Japan. With its headquarters in Basel, Switzerland, the company maintains a strong presence in its home country and is continuously exploring opportunities for growth and market expansion worldwide.

Basilea Pharmaceutica AG has achieved numerous significant milestones throughout its history. Some notable achievements include the approval of Cresemba (isavuconazole) in multiple countries for the treatment of invasive aspergillosis and mucormycosis, as well as the approval of Zevtera (ceftobiprole) for the treatment of respiratory tract infections. Additionally, Basilea has successfully advanced several late-stage development programs, such as derazantinib for the treatment of bile duct cancer and lisavanbulin for the treatment of glioblastoma. The company's commitment to research and innovation has positioned Basilea as a leader in the pharmaceutical industry, consistently achieving significant milestones to improve patient care.

Basilea Pharmaceutica AG is a Swiss biopharmaceutical company that specializes in the research and development of innovative medicines in the therapeutic areas of oncology and infectious diseases. Established in 2000, Basilea has since focused on discovering and advancing novel drugs to address unmet medical needs. With a strong commitment to scientific excellence, Basilea has made significant breakthroughs and has successfully brought several innovative drugs to the market. The company's dedication to improving patient outcomes has garnered recognition and collaborations with renowned pharmaceutical companies worldwide. Basilea Pharmaceutica AG continues to strive for cutting-edge solutions and advancements in the field of pharmaceuticals.

Basilea Pharmaceutica AG faces competition from other pharmaceutical companies in the market. Some of its main competitors include Roche Holding AG, Novartis AG, Pfizer Inc., and GlaxoSmithKline plc.

Basilea Pharmaceutica AG is primarily active in the pharmaceutical industry.

The business model of Basilea Pharmaceutica AG is focused on research, development, and commercialization of innovative pharmaceutical products to address medical needs in the therapeutic areas of oncology, hematology, and infectious diseases. The company utilizes its expertise in drug discovery and development to create novel medicines that aim to improve patient outcomes. By leveraging strategic partnerships and collaborations, Basilea Pharmaceutica AG seeks to bring these innovative therapies to market, ultimately improving the lives of patients worldwide.

Det Basilea Pharmaceutica AG Allschwil P/E-forhold er 12,52.

Basilea Pharmaceutica AG Allschwil KUV er 2,47.

AlleAktien Kvalitetsscore for Basilea Pharmaceutica AG Allschwil er 5/10.

Den forventede Basilea Pharmaceutica AG Allschwil omsætning er 193,01 mio. CHF.

Den forventede Basilea Pharmaceutica AG Allschwil indtjening er 38,06 mio. CHF.

Basilea Pharmaceutica AG is a Swiss biopharmaceutical company that focuses on the development and marketing of medications for the therapeutic field. The company is divided into three business segments: research and development, production, and marketing and sales. In the research and development area, Basilea works on new active substances for the treatment of serious diseases such as cancer, bacterial infections, and mycoses. The company utilizes modern technologies and methods such as the inhibition of signaling molecules involved in the growth of tumor cells, or the blocking of enzymes required for bacterial proliferation. The production focuses on manufacturing high-quality and high-volume drugs. Basilea adheres to the highest international standards and has state-of-the-art production facilities. In addition to its own production, the company also collaborates with external partners and licensees to achieve greater market penetration. The marketing and sales segment is responsible for product marketing and expanding into new markets. Basilea collaborates with partners both domestically and internationally to offer a wide range of products. The company employs targeted marketing to convince as many patients and doctors as possible of the benefits of their medications. Basilea's portfolio includes medications for diseases such as invasive aspergillosis, resistant staphylococcal infections, and acute myeloid leukemia. One of the company's most well-known and successful products is the active substance Ceftobiprol, which is used for the treatment of severe bacterial infections. The portfolio also includes the medications Zevtera and Cresemba, which are approved in various countries and have already been successfully marketed. In recent years, Basilea has expanded its business field through targeted investments and collaborations. For example, the company has obtained new market approvals in Europe and the USA and entered into additional distribution partnerships. Basilea has also advanced its collaboration with other companies, universities, and research institutions to drive the development of new active substances and strengthen the company's innovation power. Overall, Basilea relies on close cooperation with other companies and partners to secure market success through targeted investments and research collaborations. Through its consistent focus on the needs of patients and doctors, as well as the high innovation and quality of its products, Basilea Pharmaceutica AG is on track to become an important player in the biopharmaceutical industry.

Basilea Pharmaceutica AG Allschwil udbetaler et udbytte på 0 CHF fordelt over udbetalinger om året.

Udbyttet kan for nuværende ikke beregnes for Basilea Pharmaceutica AG Allschwil, eller selskabet udbetaler ikke udbytte.

ISIN'en for Basilea Pharmaceutica AG Allschwil er CH0011432447.

WKN for Basilea Pharmaceutica AG Allschwil er A0B9GA.

Tickeren for Basilea Pharmaceutica AG Allschwil er BSLN.SW.

I løbet af de sidste 12 måneder betalte Basilea Pharmaceutica AG Allschwil en dividende på 5,00 CHF . Dette svarer til et dividendeudbytte på omkring 12,58 %. For de kommende 12 måneder vil Basilea Pharmaceutica AG Allschwil sandsynligvis betale en dividende på 0 CHF.

Udbytteafkastet for Basilea Pharmaceutica AG Allschwil er i øjeblikket 12,58 %.

Basilea Pharmaceutica AG Allschwil betaler kvartalsvis udbytte. Dette uddeles i månederne .

Basilea Pharmaceutica AG Allschwil betalte udbytte hvert år i løbet af de sidste 0 år.

For de kommende 12 måneder forventes der dividender på 0 CHF. Dette svarer til et dividendeafkast på 0 %.

Basilea Pharmaceutica AG Allschwil bliver tildelt sektoren 'Sundhed'.

For at modtage det seneste udbytte på Basilea Pharmaceutica AG Allschwil fra den 21.6.2013 på 5 CHF, skulle du have haft aktien i din portefølje før ex-datoen den 11.4.2013.

Udbetalingen af det sidste udbytte blev foretaget den 21.6.2013.

I løbet af 2023 udbetalte Basilea Pharmaceutica AG Allschwil 0 CHF i form af dividender.

Udbytterne fra Basilea Pharmaceutica AG Allschwil udbetales i CHF.